PlexusDx says Ozempic may help liver

PlexusDx published an explainer on May 16 saying Ozempic, Novo Nordisk's brand of semaglutide, may help liver health mainly through weight loss, lower visceral fat and improved insulin sensitivity, rather than through a proven direct effect on the liver. The post said those metabolic changes may be associated with lower liver fat and improvements in liver enzymes such as ALT and AST. PlexusDx also said the evidence is still developing and that larger studies are needed to define direct hepatic benefits. The company posted the article on its educational blog, not as a regulatory filing or a clinical-trial readout. ### What exactly did PlexusDx say on May 16? The May 16 PlexusDx article said semaglutide and similar GLP-1 drugs may support "hepatic health" by reducing visceral adiposity and liver fat accumulation tied to metabolic dysfunction-associated fatty liver disease, or MASLD. The post described the effect as secondary to broader metabolic changes, not as settled proof that Ozempic directly improves liver function. (plexusdx.com) PlexusDx said randomized trials have documented changes in liver-related biomarkers, but the company added that clinical data remain limited on direct hepatic benefits from GLP-1 therapy. The post framed the findings as preliminary and said larger studies are still needed. ### Is Ozempic itself approved as a liver treatment? Ozempic's U.S. prescribing information lists the drug for glycemic control in adults with type 2 diabetes and for reducing major cardiovascular events in certain adults with type 2 diabetes and chronic kidney disease; the label does not list a liver-disease indication. (plexusdx.com) The prescribing information also includes the boxed warning on thyroid C-cell tumors seen in rodents and other established safety information. The FDA said in August 2025 that Wegovy, another semaglutide brand, was approved to treat metabolic-associated steatohepatitis, or MASH, in adults with moderate-to-advanced fibrosis. That approval was for Wegovy, not Ozempic, and it covered a defined liver-disease population. ### What evidence exists for semaglutide and liver disease? A phase 3 semaglutide trial in MASH reported that the drug outperformed placebo on measures including steatohepatitis and fibrosis in an ongoing study, according to Nature's report on the data and a gastroenterology summary of the trial design and interim analysis. (accessdata.fda.gov) Those reports described liver-specific outcomes beyond the biomarker changes highlighted in consumer explainers. (fda.gov) The FDA's approval notice said Wegovy was cleared for adults with MASH and moderate-to-advanced fibrosis, underscoring that semaglutide now has a formal U.S. regulatory role in a subset of liver disease. That is a narrower statement than saying Ozempic generally "helps the liver." ### How do liver specialists describe semaglutide's role now? The American Association for the Study of Liver Diseases said in a November 7, 2025 update that its practice guidance now includes semaglutide therapy for metabolic dysfunction-associated steatohepatitis. (nature.com) The group said the guidance addresses patient selection, comorbidity management and monitoring of safety and effectiveness. (fda.gov) AASLD-related coverage also said lifestyle modification remains the cornerstone of MASLD and MASH management alongside semaglutide. That places GLP-1 treatment within a broader care plan rather than as a stand-alone answer, according to the guidance summaries. ### What should readers take from a company blog post like this? PlexusDx presented the May 16 piece as an educational explainer on its "learn" blog, where the company also posts consumer-oriented articles on Ozempic use, safety and reviews. (aasld.org) The post did not announce new trial data, a journal publication or a regulatory action. Novo Nordisk's labeling and the FDA's MASH approval notice remain the controlling public documents on what semaglutide is approved to treat in the United States. (hepmag.com) AASLD's published guidance is the next checkpoint for how liver specialists say semaglutide should be used and monitored in practice. The PlexusDx explainer remains available on the company's learning blog as of May 16, while Ozempic prescribing information and the FDA's Wegovy MASH approval notice provide the current U.S. reference points for patients and clinicians. (plexusdx.com) (accessdata.fda.gov)